

## TREND Statement Checklist

Paper Section/ Topic	Item No	Descriptor	Reported on Page Number/Line Number	Reported on Section/Paragraph
<b>Title and Abstract</b>				
Title and Abstract	1	• Information on how unit were allocated to interventions	Page4-5/line 28-34 1-12	Methods/Paragraph1
		• Structured abstract recommended	Page2-3/line 10-34 1-2	Abstract/Paragraph1-4
		• Information on target population or study sample	Page4-5/line 28-34 1-12	Methods/Paragraph1
<b>Introduction</b>				
Background	2	• Scientific background and explanation of rationale	Page2/line 10-17	Abstract/Paragraph1
		• Theories used in designing behavioral interventions	Page2/line 18-28	Abstract/Paragraph 2
<b>Methods</b>				
Participants	3	• Eligibility criteria for participants, including criteria at different levels in recruitment/sampling plan (e.g., cities, clinics, subjects)	Page4-5/line 28-34 1-12	Methods/Paragraph1
		• Method of recruitment (e.g., referral, self-selection), including the sampling method if a systematic sampling plan was implemented	Page4/line 28-34	Methods/Paragraph1
		• Recruitment setting	Page4/line 28-34	Methods/Paragraph1
		• Settings and locations where the data were collected	Page4/line 28-34	Methods/Paragraph1
Interventions	4	• Details of the interventions intended for each study condition and how and when they were actually administered, specifically including:	Page 5/line 17-28	Methods/Paragraph 2
		o Content: what was given?	Page 5/line 17-28	Methods/Paragraph 2
		o Delivery method: how was the content given?	Page 5/line 17-28	Methods/Paragraph 2
		o Unit of delivery: how were the subjects grouped during delivery?	Page 5/line 17-28	Methods/Paragraph 2
		o Deliverer: who delivered the intervention?	Page 5/line 17-28	Methods/Paragraph 2
		o Setting: where was the intervention delivered?	Page 5/line 17-28	Methods/Paragraph 2
		o Exposure quantity and duration: how many sessions or episodes or events were intended to be delivered? How long were they intended to last?	Page 6-7/line 30-34 1-11	Results/Paragraph2-3

		<ul style="list-style-type: none"> <li>o Time span: how long was it intended to take to deliver the intervention to each unit?</li> </ul>	Page 6-7/line 30-34 1-11	Results/Paragraph2-3
		<ul style="list-style-type: none"> <li>o Activities to increase compliance or adherence (e.g., incentives)</li> </ul>	Didn't have	Didn't have
Objectives	5	<ul style="list-style-type: none"> <li>• Specific objectives and hypotheses</li> </ul>	Page 4/line16-20	Introduction/Paragraph 2
Outcomes	6	<ul style="list-style-type: none"> <li>• Clearly defined primary and secondary outcome measures</li> </ul>	Page 6/line 7-12	Methods/Paragraph 4
		<ul style="list-style-type: none"> <li>• Methods used to collect data and any methods used to enhance the quality of measurements</li> </ul>	Page 6/line 16-19	Methods/Paragraph 5
		<ul style="list-style-type: none"> <li>• Information on validated instruments such as psychometric and biometric properties</li> </ul>	Page 6/line 16-19	Methods/Paragraph 5
Sample Size	7	<ul style="list-style-type: none"> <li>• How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules</li> </ul>		
Assignment Method	8	<ul style="list-style-type: none"> <li>• Unit of assignment (the unit being assigned to study condition, e.g., individual, group, community)</li> </ul>	Page 5/line 17-28	Methods/Paragraph 2
		<ul style="list-style-type: none"> <li>• Method used to assign units to study conditions, including details of any restriction (e.g., blocking, stratification, minimization)</li> </ul>	Page 5/line 17-28	Methods/Paragraph 2
		<ul style="list-style-type: none"> <li>• Inclusion of aspects employed to help minimize potential bias induced due to non-randomization (e.g., matching)</li> </ul>	Page 5/line 17-28	Methods/Paragraph 2
Blinding (masking)	9	<ul style="list-style-type: none"> <li>• Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to study condition assignment; if so, statement regarding how the blinding was accomplished and how it was assessed.</li> </ul>	This is not a blinding study.	This is not a blinding study.
Unit of Analysis	10	<ul style="list-style-type: none"> <li>• Description of the smallest unit that is being analyzed to assess intervention effects (e.g., individual, group, or community)</li> </ul>	Didn't have	Didn't have
		<ul style="list-style-type: none"> <li>• If the unit of analysis differs from the unit of assignment, the analytical method used to account for this (e.g., adjusting the standard error estimates by the design effect or using multilevel analysis)</li> </ul>	Didn't have	Didn't have
Statistical Methods	11	<ul style="list-style-type: none"> <li>• Statistical methods used to compare study groups for primary methods outcome(s), including complex methods of correlated data</li> </ul>	Page 6/line 16-19	Methods/Paragraph 6
		<ul style="list-style-type: none"> <li>• Statistical methods used for additional analyses, such as a subgroup analyses and adjusted analysis</li> </ul>	Page 6/line 16-19	Methods/Paragraph 6
		<ul style="list-style-type: none"> <li>• Methods for imputing missing data, if used</li> </ul>	Page 6/line 16-19	Methods/Paragraph 6
		<ul style="list-style-type: none"> <li>• Statistical software or programs used</li> </ul>	Page 6/line 16-19	Methods/Paragraph 6
<b>Results</b>				
Participant flow	12	<ul style="list-style-type: none"> <li>• Flow of participants through each stage of the study: enrollment, assignment, allocation, and intervention exposure, follow-up, analysis (a diagram is strongly recommended)</li> </ul>	Page4-5/line 28-34 1-12	Methods/Paragraph1
		<ul style="list-style-type: none"> <li>o Enrollment: the numbers of participants screened for eligibility, found to be eligible or not eligible, declined to be enrolled, and enrolled in the study</li> </ul>	Page 6/ line 24-26	Results/Paragraph 1 Figure 1

		<ul style="list-style-type: none"> <li>o Assignment: the numbers of participants assigned to a study condition</li> </ul>	Page 6/ line 24-26	Page 6/ line 24-26
		<ul style="list-style-type: none"> <li>o Allocation and intervention exposure: the number of participants assigned to each study condition and the number of participants who received each intervention</li> </ul>	Page 6/ line 24-26	Results/Paragraph 1 Figure 1
		<ul style="list-style-type: none"> <li>o Follow-up: the number of participants who completed the follow-up or did not complete the follow-up (i.e., lost to follow-up), by study condition</li> </ul>	Page 6/ line 24-26	Results/Paragraph 1 Figure 1
		<ul style="list-style-type: none"> <li>o Analysis: the number of participants included in or excluded from the main analysis, by study condition</li> </ul>	Page 6/ line 24-26	Results/Paragraph 1
		<ul style="list-style-type: none"> <li>• Description of protocol deviations from study as planned, along with reasons</li> </ul>	Page 6/ line 24-26	Results/Paragraph 1
Recruitment	13	<ul style="list-style-type: none"> <li>• Dates defining the periods of recruitment and follow-up</li> </ul>	Page 4/line 28	Methods/Paragraph1
Baseline Data	14	<ul style="list-style-type: none"> <li>• Baseline demographic and clinical characteristics of participants in each study condition</li> </ul>	Page 6/ line 24-26	Results/Paragraph 1
		<ul style="list-style-type: none"> <li>• Baseline characteristics for each study condition relevant to specific disease prevention research</li> </ul>	Page 6/ line 24-26	Results/Paragraph 1
		<ul style="list-style-type: none"> <li>• Baseline comparisons of those lost to follow-up and those retained, overall and by study condition</li> </ul>	Page 6/ line 24-26	Results/Paragraph 1
		<ul style="list-style-type: none"> <li>• Comparison between study population at baseline and target population of interest</li> </ul>	Page 6/ line 24-26	Results/Paragraph 1
Baseline equivalence	15	<ul style="list-style-type: none"> <li>• Data on study group equivalence at baseline and statistical methods used to control for baseline differences</li> </ul>	Page 6/ line 24-26	Results/Paragraph 1
Numbers analyzed	16	<ul style="list-style-type: none"> <li>• Number of participants (denominator) included in each analysis for each study condition, particularly when the denominators change for different outcomes; statement of the results in absolute numbers when feasible</li> </ul>	Page 6/ line 24-26	Results/Paragraph 1
		<ul style="list-style-type: none"> <li>• Indication of whether the analysis strategy was “intention to treat” or, if not, description of how non-compliers were treated in the analyses</li> </ul>	Page 6/ line 24-26	Results/Paragraph 1
Outcomes and estimation	17	<ul style="list-style-type: none"> <li>• For each primary and secondary outcome, a summary of results for each estimation study condition, and the estimated effect size and a confidence interval to indicate the precision</li> </ul>	Page 6-7/line 30-34 1-11	Results/Paragraph2-3
		<ul style="list-style-type: none"> <li>• Inclusion of null and negative findings</li> </ul>	Page 6-7/line 30-34 1-11	Results/Paragraph2-3
		<ul style="list-style-type: none"> <li>• Inclusion of results from testing pre-specified causal pathways through which the intervention was intended to operate, if any</li> </ul>	this research didn't have results from testing	didn't have
Ancillary analyses	18	<ul style="list-style-type: none"> <li>• Summary of other analyses performed, including subgroup or restricted analyses, indicating which are pre-specified or exploratory</li> </ul>	Didn't have.	Didn't have
Adverse events	19	<ul style="list-style-type: none"> <li>• Summary of all important adverse events or unintended effects in each study condition (including summary measures, effect size estimates, and confidence intervals)</li> </ul>	Page 7/line 15-18	Toxic effects/Paragraph1

DISCUSSION				
Interpretation	20	<ul style="list-style-type: none"> <li>• Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study</li> </ul>	Page11/line 21-27	Limitations/Paragraph 1
		<ul style="list-style-type: none"> <li>• Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations</li> </ul>	Page11/line 23-33	Discussion/Paragraph 6
		<ul style="list-style-type: none"> <li>• Discussion of the success of and barriers to implementing the intervention, fidelity of implementation</li> </ul>	Page 9-10/line 25-34 1	Discussion/Paragraph 5
		<ul style="list-style-type: none"> <li>• Discussion of research, programmatic, or policy implications</li> </ul>	Page11/line 4-17	Discussion/Paragraph 7
Generalizability	21	<ul style="list-style-type: none"> <li>• Generalizability (external validity) of the trial findings, taking into account the study population, the characteristics of the intervention, length of follow-up, incentives, compliance rates, specific sites/settings involved in the study, and other contextual issues</li> </ul>	Page 2/line 29-34	Abstract/Paragraph 3
Overall Evidence	22	<ul style="list-style-type: none"> <li>• General interpretation of the results in the context of current evidence and current theory</li> </ul>	Page11-12/line31-34 1-5	Conclusions/Paragraph 1

**From:** Des Jarlais, D. C., Lyles, C., Crepaz, N., & the Trend Group (2004). Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. *American Journal of Public Health*, 94, 361-366. For more information, visit: <http://www.cdc.gov/trendstatement/>

Article information: <http://dx.doi.org/10.21037/apm-21-443>

\*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.